Personalized cancer vaccines (PCVs) are opening a new era in treatment. Using mRNA technology, patient-specific vaccines can be designed and produced in just weeks, priming the immune system to recognize and attack tumor mutations before the cancer can adapt.
Rapid access to high-quality DNA templates is essential as they are the starting material for mRNA production. Any delay in obtaining DNA directly slows development—a critical concern when producing personalized cancer vaccines on a tight timeline of just a few weeks.
Learn how ENFINIA™ IVT Ready DNA helps keep the process moving.
STEP ONE
DAYS ⇒ WEEKS
Patient Biopsy
A sample is collected from the patient’s tumor.
STEP TWO
WEEKS
Sequencing and Analysis
Researchers analyze DNA and RNA from both tumor and healthy cells, using bioinformatics and AI to pinpoint cancer-specific neoantigens.
STEP THREE
WEEKS
Vaccine Production and Testing
Based on the neoantigen analysis, a personalized mRNA vaccine is quickly manufactured using platform technology.
How Elegen Helps
Rapid DNA template generation is essential. Traditional plasmid methods are slow and create bottlenecks that delay manufacturing. ENFINIA IVT Ready DNA is a high-quality, cell-free solution that can be synthesized quickly and used seamlessly with leading cGMP RNA manufacturers.
STEP FOUR
WEEKS
Administration to Patients & Re-dosing
The vaccine is delivered to the clinic and administered to the patient. Boosters may be needed to reinforce and amplify the immune response.
How Elegen Helps
Elegen can provide ENFINIA IVT Ready templates at scale for multiple doses.
Personalized cancer vaccine development requires obtaining DNA templates quickly– putting significant pressure on the speed and quality of DNA synthesis. Unfortunately, DNA synthesis vendors often become a bottleneck.
At Elegen, we’ve broken this bottleneck, delivering long, complex, NGS-verified DNA in a matter of days, eliminating the cloning delays, sequence rejections, and synthesis limitations that often slow down construct design and testing.
Whether you’re developing vaccines to combat infectious disease or cancer, Elegen enables faster iteration, broader construct screening, and greater reliability, helping researchers make go/no-go decisions earlier and reduce time-to-clinic.
Linear fragments up to 5.5 kb, shipped as fast as 10 business days
No endotoxin risk; no linearization or purification required
Reaction-ready format for faster in vitro transcription and testing
Rapidly test diverse sequence complexities and poly(A) tail designs (including segmented formats)
Built using Elegen’s patented cell-free DNA manufacturing technology
NGS-verified, high-fidelity constructs
